Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse

PLoS Computational Biology

Volumn 8, Issue 7, 2012, Pages

  Zheng, Fang ^a   Zhan, Chang Guo ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY;

DRUG ABUSE; DRUG METABOLISMS; DRUG OF ABUSE; DRUG-METABOLIZING ENZYMES; ENZYME THERAPY; HALF LIVES; IN-VITRO; PHARMACOKINETIC MODELING; PHYSIOLOGICAL EFFECTS; VITRO KINETICS;

PHARMACOKINETICS;

DRUG METABOLIZING ENZYME; ESTERASE; HYDROLASE;

ARTICLE; BRAIN LEVEL; COCAINE DEPENDENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABUSE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME THERAPY; HALF LIFE TIME; THEORETICAL MODEL;

EID: 84864584295     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002610     Document Type: Article

References (62)

1. Chawla S (United Nations Office on Drugs and Crime) (2010) World Drug Report 2010. Report June 2010-1,700 New York, (N.Y.) United Nations. United Nations Publication, Sales No. E.10.XI.13.
2. National Institute on Drug Abuse (2011) Understanding Drug Abuse and Addiction. Report March 2011 Washington (D.C.) U.S. Department of Health & Human Services. Web Publication Available online (http://www.drugabuse.gov/infofacts/understand.html).
3. Schmitt KC, Reith MEA, (2010) Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse. Ann NY Acad Sci 1187: 316-340.
4. Gorelick DA, (2008) Pharmacokinetic approaches to treatment of drug addiction. Expert Rev Clin Pharmacol 1: 277-290.
5. Moreno AY, Janda HD, (2009) Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 92: 199-205.
6. Huang X, Zhan C-G, (2007) How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys J 93: 3627-3639.
7. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
8. Huang X, Gu H, Zhan C-G, (2009) Mechanism for cocaine blocking the transport of dopamine: Insights from molecular modeling and dynamics simulations. J Phys Chem B 113: 15057-15066.
9. Zheng F, Zhan CG, (2011) Enzyme-therapy approaches for the treatment of drug overdose and addiction. Future Med Chem 3: 9-13.
10. Gorelick DA, (1997) Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48: 159-165.
11. Landry DW, Zhao K, Yang GXQ, Glickman M, Georgiadis TM, (1993) Antibody-Catalyzed Degradation of Cocaine. Science 259: 1899-1901.
12. Mendelson JH, Mello NK, (1996) Drug therapy: Management of cocaine abuse and dependence. New England J Med 334: 965-972.
13. Preston KL, Vahabzadeh M, Schmittner J, Lin JL, Gorelick DA, et al. (2009) Cocaine craving and use during daily life. Psychopharmacology 207: 291-301.
14. Zhan CG, Deng SX, Skiba JG, Hayes BA, Tschampel SM, et al. (2005) First-principle studies of intermolecular and intramolecular catalysis of protonated cocaine. J Comput Chem 26: 980-986.
15. Meijler MM, Kaufmann GF, Qi LW, Mee JM, Coyle AR, et al. (2005) Fluorescent cocaine probes: A tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc 127: 2477-2484.
16. Bresler MM, Rosser SJ, Basran A, Bruce NC, (2000) Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp strain MB1. Appl Env Microbiol 66: 904-908.
17. Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, et al. (2002) Crystal structure of a bacterial cocaine esterase. Nature Struct Biol 9: 17-21.
18. Turner JM, Larsen NA, Basran A, Barbas CF, Bruce NC, et al. (2002) Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41: 12297-12307.
19. Deng SX, de Prada P, Landry DW, (2002) Anticocaine catalytic antibodies. J Immunol Methods 269: 299-310.
20. Xie WH, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, et al. (1999) An improved cocaine hydrolase: The A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55: 83-91.
21. Sun H, Pang YP, Lockridge O, Brimijoin S, (2002) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 62: 220-224.
22. Hamza A, Cho H, Tai HH, Zhan CG, (2005) Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J Phys Chem B 109: 4776-4782.
23. Zhan CG, Gao D, (2005) Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine. Biophys J 89: 3863-3872.
24. Gao DQ, Narasimhan DL, Macdonald J, Brim R, Ko MC, et al. (2009) Thermostable Variants of Cocaine Esterase for Long-Time Protection against Cocaine Toxicity. Mol Pharmacol 75: 318-323.
25. Zhan CG, (2009) Novel pharmacological approaches to treatment of drug overdose and addiction. Expert Rev Clin Pharmacol 2: 1-4.
26. Zheng F, Zhan C-G, (2009) Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anticocaine medications. Future Med Chem 1: 515-528.
27. Zheng F, Zhan CG, (2008) Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction. Org Biomole Chem 6: 836-843.
28. Pan YM, Gao DQ, Yang WC, Cho H, Yang GF, et al. (2005) Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Nat Acad Sci U S A 102: 16656-16661.
29. Yang W, Xue L, Fang L, Chen X, Zhan CG, (2010) Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact 187: 148-152.
30. Zheng F, Yang WC, Ko MC, Liu JJ, Cho H, et al. (2008) Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130: 12148-12155.
31. Yang WC, Pan YM, Zheng F, Cho H, Tai HH, et al. (2009) Free-Energy Perturbation Simulation on Transition States and Redesign of Butyrylcholinesterase. Biophys J 96: 1931-1938.
32. Xue L, Ko MC, Tong M, Yang WC, Hou SR, et al. (2011) Design, Preparation, and Characterization of High-Activity Mutants of Human Butyrylcholinesterase Specific for Detoxification of Cocaine. Mol Pharmacol 79: 290-297.
33. Brim RL, Nance MR, Youngstrom DW, Narasimhan D, Zhan CG, et al. (2010) A Thermally Stable Form of Bacterial Cocaine Esterase: A Potential Therapeutic Agent for Treatment of Cocaine Abuse. Mol Pharmacol 77: 593-600.
34. Collins GT, Brim RL, Narasimhan D, Ko MC, Sunahara RK, et al. (2009) Cocaine Esterase Prevents Cocaine-Induced Toxicity and the Ongoing Intravenous Self-Administration of Cocaine in Rats. J Pharmacol Exp Ther 331: 445-455.
35. Zheng F, Yang W, Xue L, Hou S, Liu J, et al. (2010) Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency. Biochemistry 49: 9113-9119.
36. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, et al. (2008) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33: 2715-2725.
37. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. (1989) Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 4: 371-377.
38. Gatley SJ, (1991) Activities of the Enantiomers of Cocaine and Some Related-Compounds as Substrates and Inhibitors of Plasma Butyrylcholinesterase. Biochem Pharmacol 41: 1249-1254.
39. Walter E, (1982) Identifiability of State Space Models New York Springer-Verlag.
40. Bonate PL, (2006) Pharmacokinetic-Pharmacodynamic Modeling and Simulation New York Springer.
41. Cobelli C, Carson ER, (2008) Introduction to Modeling in Physiology and Medicine San Diego Academic Press.
42. Cook CE, Jeffcoat AR, Perez-Reyes M, (1985) Pharmacokinetic studies of cocaine and phencyclidine in man. In: Barnett G, Chiang CN, editors. in Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs Foster City, California Biomedical Publications pp. 48-74.
43. Fowler JS, Kroll C, Ferrieri R, Alexoff D, Logan J, et al. (2007) PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J Nucl Med 48: 1724-1732.
44. D'Argenio DZ, Schumitzky A, (1997) ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software Los Angeles Biomedical Simulations Resource.
45. Zheng F, (2004) Computational modeling of the EGF receptor signaling network [M.Sc. Thesis] Pullman (Washington) Department of Computer Science, Washington State University.
46. Miller JH, Zheng F, (2004) Large-scale simulations of cellular signaling processes. Parallel Comput 30: 1137-1149.
47. Miller JH, Zheng F, Jin S, Opresko LK, Wiley HS, et al. (2005) A Model of Cytokine Shedding Induced by Low Doses of Gamma Radiation. Radiat Res 163: 337-342.
48. Lockridge O, Schopfer LM, Winger G, Woods JH, (2005) Large-Scale Purification of Butyrylcholinesterase from Human Plasma Suitable for Injection into Monkeys; a Potential New Therapeutic for Protection against Cocaine and Nerve Agent Toxicity. J Med Chem Biol Radiol Defense 3: 1-20.
49. Ngamelue MN, Homma K, Lockridge O, Asojo OA, (2007) Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. Acta Crystallogr F-Struct Biol Cryst Commun 63: 723-727.
50. Pan YM, Muzyka JL, Zhan CG, (2009) Model of Human Butyrylcholinesterase Tetramer by Homology Modeling and Dynamics Simulation. J Phys Chem B 113: 6543-6552.
51. Vaisi-Raygani A, Rahimi Z, Kharazi H, Tavilani H, Aminiani M, et al. (2007) Determination of butyrylcholinesterase (BChE) phenotypes to predict the risk of prolonged apnea in persons receiving succinylcholine in the healthy population of western Iran. Clin Biochem 40: 629-633.
52. Yin D, Valles F, Fiandaca M, Forsayeth J, Larson P, et al. (2009) Striatal volume differences between non-human and human primates. J Neurosci Methods 176: 200-205.
53. Hedaya M, Pan W, (1997) Cocaine pharmacokinetics/pharmacodynamics in awake freely moving rats. Pharm Res 14: 1099-1102.
54. Pan W, Hedaya M, (1998) An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. J Pharmacol Exp Ther 39: 1-8.
55. Lu H-T, Chen X, Zhan C-G, (2007) First-principles calculation of pKa for cocaine, nicotine, neurotransmitters, and anilines in aqueous solution. J Phys Chem B 111: 10599-10605.
56. Gao Y, Brimijoin S, (2009) Lasting Reduction of Cocaine Action in Neostriatum-A Hydrolase Gene Therapy Approach. J Pharmacol Exp Ther 330: 449-457.
57. Barnett G, Hawks R, Resnick R, (1981) Cocaine Pharmacokinetics in Humans. J Ethnopharmacol 3: 353-366.
58. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S, (2010) The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact 187: 421-424.
59. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, et al. (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386: 827-830.
60. Jufer RA, Walsh SL, Cone EJ, (1998) Cocaine and metabolite concentrations in plasma during repeated oral administration: Development of a human laboratory model of chronic cocaine use. J Anal Toxicol 22: 435-444.
61. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, et al. (2001) Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase- Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J Biol Chem 276: 9330-9336.
62. Gatley SJ, MacGregor RR, Fowler JS, Wolf AP, Dewey SL, et al. (1990) Rapid stereoselective hydrolysis of (+)-cocaine in baboon plasma prevents its uptake in the brain: implications for behavioral studies. J Neurochem 54: 720-723.